Logo image of DARE

DARE BIOSCIENCE INC (DARE) Stock Fundamental Analysis

NASDAQ:DARE - Nasdaq - US23666P2002 - Common Stock - Currency: USD

2.26  -0.14 (-5.83%)

Premarket: 2.26 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to DARE. DARE was compared to 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of DARE have multiple concerns. DARE is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year DARE has reported negative net income.
DARE had a positive operating cash flow in the past year.
In the past 5 years DARE always reported negative net income.
In the past 5 years DARE reported 4 times negative operating cash flow.
DARE Yearly Net Income VS EBIT VS OCF VS FCFDARE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

The Return On Assets of DARE (-9.00%) is better than 69.43% of its industry peers.
Industry RankSector Rank
ROA -9%
ROE N/A
ROIC N/A
ROA(3y)-76.89%
ROA(5y)-132.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DARE Yearly ROA, ROE, ROICDARE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K -4K -6K -8K

1.3 Margins

DARE's Gross Margin of 108.60% is amongst the best of the industry. DARE outperforms 99.48% of its industry peers.
The Profit Margin and Operating Margin are not available for DARE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 108.6%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DARE Yearly Profit, Operating, Gross MarginsDARE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50K -100K -150K -200K

More info and screens

3

2. Health

2.1 Basic Checks

DARE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DARE has been increased compared to 1 year ago.
The number of shares outstanding for DARE has been reduced compared to 5 years ago.
The debt/assets ratio for DARE is higher compared to a year ago.
DARE Yearly Shares OutstandingDARE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
DARE Yearly Total Debt VS Total AssetsDARE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -17.58, we must say that DARE is in the distress zone and has some risk of bankruptcy.
DARE has a Altman-Z score of -17.58. This is in the lower half of the industry: DARE underperforms 78.24% of its industry peers.
DARE has a debt to FCF ratio of 1.20. This is a very positive value and a sign of high solvency as it would only need 1.20 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 1.20, DARE belongs to the top of the industry, outperforming 95.34% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 1.2
Altman-Z -17.58
ROIC/WACCN/A
WACC9.16%
DARE Yearly LT Debt VS Equity VS FCFDARE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

DARE has a Current Ratio of 0.56. This is a bad value and indicates that DARE is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of DARE (0.56) is worse than 91.19% of its industry peers.
DARE has a Quick Ratio of 0.56. This is a bad value and indicates that DARE is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.56, DARE is not doing good in the industry: 89.12% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.56
Quick Ratio 0.56
DARE Yearly Current Assets VS Current LiabilitesDARE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

DARE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 95.31%, which is quite impressive.
DARE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -96.82%.
EPS 1Y (TTM)95.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.48%
Revenue 1Y (TTM)-96.82%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%182.56%

3.2 Future

The Earnings Per Share is expected to grow by 98.26% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 219.09% on average over the next years. This is a very strong growth
EPS Next Y-284.95%
EPS Next 2Y-38.17%
EPS Next 3Y45.17%
EPS Next 5Y98.26%
Revenue Next Year419.65%
Revenue Next 2Y254.45%
Revenue Next 3Y270.28%
Revenue Next 5Y219.09%

3.3 Evolution

DARE Yearly Revenue VS EstimatesDARE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
DARE Yearly EPS VS EstimatesDARE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -100 -200 -300 -400 -500

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DARE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DARE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DARE Price Earnings VS Forward Price EarningsDARE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

98.96% of the companies in the same industry are more expensive than DARE, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 3.33
EV/EBITDA N/A
DARE Per share dataDARE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

DARE's earnings are expected to grow with 45.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-38.17%
EPS Next 3Y45.17%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DARE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DARE BIOSCIENCE INC

NASDAQ:DARE (8/6/2025, 8:17:28 PM)

Premarket: 2.26 0 (0%)

2.26

-0.14 (-5.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-11 2025-08-11
Inst Owners9.4%
Inst Owner Change0%
Ins Owners1.15%
Ins Owner Change0%
Market Cap20.00M
Analysts80
Price Target13.26 (486.73%)
Short Float %12.73%
Short Ratio0.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2%
Min EPS beat(2)-19.49%
Max EPS beat(2)15.48%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-98.2%
Min Revenue beat(2)-104.71%
Max Revenue beat(2)-91.69%
Revenue beat(4)0
Avg Revenue beat(4)-99.03%
Min Revenue beat(4)-104.71%
Max Revenue beat(4)-91.69%
Revenue beat(8)1
Avg Revenue beat(8)-58.63%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-15.26%
EPS NY rev (1m)3.17%
EPS NY rev (3m)2.69%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-37.11%
Revenue NY rev (1m)-25.01%
Revenue NY rev (3m)551.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 223.47
P/FCF 3.33
P/OCF 2.97
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.18
EYN/A
EPS(NY)-0.99
Fwd EYN/A
FCF(TTM)0.68
FCFY30.07%
OCF(TTM)0.76
OCFY33.68%
SpS0.01
BVpS-1.08
TBVpS-1.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 108.6%
FCFM 6719.11%
ROA(3y)-76.89%
ROA(5y)-132.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 1.2
Debt/EBITDA N/A
Cap/Depr 381.33%
Cap/Sales 807.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.56
Quick Ratio 0.56
Altman-Z -17.58
F-Score3
WACC9.16%
ROIC/WACCN/A
Cap/Depr(3y)1097.89%
Cap/Depr(5y)675.4%
Cap/Sales(3y)1956.65%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.48%
EPS Next Y-284.95%
EPS Next 2Y-38.17%
EPS Next 3Y45.17%
EPS Next 5Y98.26%
Revenue 1Y (TTM)-96.82%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%182.56%
Revenue Next Year419.65%
Revenue Next 2Y254.45%
Revenue Next 3Y270.28%
Revenue Next 5Y219.09%
EBIT growth 1Y23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y127.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y130.8%
OCF growth 3YN/A
OCF growth 5YN/A